Bristol-Myers Squibb Co. (NYSE:BMY) shares are trading higher on Wednesday as the company is announcing a strategic agreement with Anthropic to deploy AI across its operations.



The collaboration aims to enhance the discovery and development of new medicines, leveraging Anthropic’s advanced AI capabilities to connect over 30,000 employees with critical institutional knowledge.



<h2>Bristol-Myers Squibb Partners With Anthropic To Deploy AI</h2>



The partnership with Anthropic marks a significant step for Bristol-Myers Squibb in integrating AI into its workflows, focusing on areas expected to yield high impact.



<div>




Read Also:

Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma




</div>


The initiative builds on over three years of AI investment at the company, aiming to streamline processes in research, clinical development, and manufacturing.



Last week, Tempus AI Inc. (NASDAQ:TEM) announced a new collaboration initiative with Bristol Myers Squibb aimed at improving clinical trial design and increasing the Probability of Technical &amp; Regulatory Success across five initial development programs.



The companies plan to use artificial intelligence, multimodal real-world data, and advanced data science tools to refine drug development strategies in oncology and neuroscience.



The initiative will leverage Tempus’ AI-enabled analytical platform, Lens, to analyze a large library of de-identified multimodal patient records.



The companies said the collaboration is intended to strengthen Bristol Myers Squibb’s development portfolio by testing trial assumptions, identifying appropriate patient populations, and improving control group validation.



<h2>Top ETFs Holding Bristol-Myers Squibb Stock</h2>



<ul>
<li>Invesco S&amp;P Ultra Dividend Revenue ETF (NYSE:RDIV): 5.42% Weight</li>



<li>VanEck Pharmaceutical ETF (NASDAQ:PPH): 4.64% Weight</li>



<li>iShares US Pharmaceutical ETF (NYSE:IHE): 4.63% Weight</li>
</ul>



Significance: Because BMY carries significant weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.



BMY Price Action: Bristol-Myers Squibb shares were up 0.12% at $58.38 at the time of publication on Wednesday, according to Benzinga Pro data.



Photo: Shutterstock



<div>



Read Also:

Intuit Stock Falls After Report Says Company To Cut 17% Of Workforce



</div>

IBBQ

SBIO

LABU

ARKG

Bristol-Myers Squibb Co. (NYSE:BMY) announced a strategic partnership with Anthropic to enhance drug discovery using AI, leading to a slight increase in shares. This collaboration aims to integrate AI into various workflows, building on three years of AI investment. Additionally, a partnership with Tempus AI Inc. focuses on improving clinical trial design and success rates in oncology and neuroscience. BMY shares rose 0.12% to $58.38 on Wednesday.

Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery